Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting GlobeNewswire November 07, 2025 Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for […]